BioNexus Gene Lab alleges unlawful proxy solicitation; stock plan and reverse split fail

BioNexus Gene Lab Corp

Three director nominees re-elected despite significant against votes (Su-Leng Tan Lee: 4.1M for vs 6.3M against).
Auditor JP Centurion & Partners reappointed with 10,720,634 votes for.
2024 Stock Incentive Plan not approved: 4,094,117 for, 6,382,176 against.
Reverse stock split (1:2 to 1:10) not approved: 4,371,573 for, 6,378,201 against.
Company alleges former officer/director directed unlawful proxy solicitation affecting Proposals 3&4; board authorized investigation, may pursue litigation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.